Increasing cancer incidence increases the demand for drug delivery systems. This will likely contribute significantly to the market's growth during the forecast period. Technological Advancements ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Acne Vulgaris Therapeutics Market Size in the 7MM was ~USD 4,256 Million in 2023 and is projected to ...

When big pharmaceutical companies merge, the perception is that drug prices rise, but a University of Iowa study finds that’s ...

(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

The key Ulcerative Colitis therapies expected to launch in the market include Jyseleca (filgotinib), Rinvoq (Upadacitinib), ...

Medicare spending on cancer drugs may not be associated with the drugs’ clinical benefits, such as overall survival or progression-free survival.

With demand for GLP-1 drugs booming, compounding pharmacies and telehealth companies like Hims and Ro have jumped into the market ... depending on their size, to phase out their products.

An analysis of oncology drugs approved in the United States found that Medicare spending was predominantly driven by the market, not a drug’s therapeutic value.